STAT

Once widely criticized, the Wuhan quarantine bought the world time to prepare for Covid-19

Early evidence is causing some public health experts to reconsider their initial scathing criticism of quarantines and travel restrictions intended to combat the novel coronavirus.
A doctor looks at a lung CT scan at a hospital in the quarantine zone in Wuhan, China.

Could cause panic.” “Will not help end the crisis.” “Could backfire.”

When the Chinese government blocked most travel into and out of the city at the center of the Covid-19 outbreak in late January, many public health experts took to social media and op-ed pages to decry the measure as not only draconian and a violation of individual rights but also as ineffective: This largest quarantine in history — the city, Wuhan, has a population of 11 million, and the lockdown has been expanded — would have little effect on the course of the epidemic, they argued.

As the U.S. and other countries imposed travel restrictions, even the World Health Organization questioned whether they were a good idea. But early evidence is causing some disease fighters to reconsider.

The last few days have seen a perceptible flattening in growth of Covid-19 cases in China, raising hopes that the epidemic has peaked. (Though there are about the accuracy of China’s count.) That supports the emerging consensus on the Wuhan quarantine in particular: that, at minimum, it bought China and the world time to prepare. Crucially,

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related Books & Audiobooks